Amgen

RIABNI

ASP | WAC | AWP at the HCPCS Unit

Manufacturer:

Amgen

Riabni HCPCS:

Q5123

HCPCS Code Descriptor:

Injection, rituximab-arrx, biosimilar, (riabni), 10 mg

Category:

Q Code

Riabni NDCs:

55513-0326-01, 55513-0224-01

Primary Type:

Oncology Biosimilar

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Riabni CPT Codes:

Potential CPT administration codes for Riabni can be found at the following link.

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Riabni:

RIABNI is an Oncology Biosimilar drug manufactured by Amgen and administered via the Intravenous route of administration. The Q Code: Q5123 is aligned to the drug RIABNI.

Riabni is a biosimilar for the reference drug Avastin (J9035)

ACCESS PRICING AND MORE BY REGISTERING

Q5123 Added Date:

July 1, 2021

Q5123 Effective Date:

July 1, 2021

Q5123 Termination Date:

HCPCS Active

Riabni billing and coding information can be found through Amgen at the link below:
Riabni patient assistance information can be found through Amgen Assist at the URL: https://www.amgenassist.com/copay
RIABNI prescribing information can be found at the link below:
Information regarding RIABNI’s side effects can be found at MedlinePlus